MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine dysregulation syndrome"

  • 2024 International Congress

    Dopamine Dysregulation in Parkinson’s Disease and Substance Use: Therapeutic Use and Compulsive Behaviors Thin Line

    J. Hall, R. Islam, D. Nolasco, B. Carr (GAINESVILLE, USA)

    Objective: Parkinson's Disease (PD) inherently disrupts dopaminergic transmission, primarily within the nigrostriatal pathway, necessitating dopaminergic therapies. However, these therapies can lead to Dopamine Dysregulation Syndrome…
  • 2024 International Congress

    Two unusual cases of dopamine dysregulation syndrome in patients with Parkinson’s disease

    L. Lachance, P. Huot (Montreal, Canada)

    Objective: To present two cases of dopamine dysregulation syndrome (DDS) in patients with Parkinson’s disease (PD) who took extreme measures to access more dopaminergic medication.…
  • 2024 International Congress

    Dopamine Dysregulation Syndrome Outcomes following Pallidal Deep Brain Stimulation in Parkinson’s Disease

    N. David, S. Factor, R. Tripathi, L. Higginbotham (Atlanta, USA)

    Objective: To examine the impact of pallidal deep brain stimulation (DBS) on symptoms of Dopamine Dysregulation Syndrome (DDS) in Parkinson’s disease (PD). Background: DDS is…
  • 2023 International Congress

    Impulse Control Disorder and medication management in Patients with Early-Onset Parkinson’s Disease

    J. Jacobson, K. Ghoniem, A. Mullan, P. Turcano, C. Stang, E. Camerucci, C. Piat, J. Bower, R. Savica (Rochester, USA)

    Objective: To assess the usage frequency of dopamine agonists (DA), the prevalence of impulse control disorder (ICD) in patients with Early-onset Parkinson’s Disease (EOPD), and…
  • 2023 International Congress

    Dopamine dysregulation syndrome in Parkinson’s disease controlled by safinamine

    SK. Song, JH. Kang (Jeju-Si, Republic of Korea)

    Objective: To describe a case of dopamine dysregulation syndrome managed by safinamide. Background: Dopamine dysregulation syndrome (DDS) is an uncommon non-motor symptom of Parkinson disease…
  • 2022 International Congress

    Predictors of relapse in impulse control disorders in patients with Parkinson’s disease.

    L. Gaibor, D. Vazquez, H. Estrada (CDMX, Mexico)

    Objective: Identify predictors of relapse in impulse control disorders (ICD) in patients with Parkinson's disease. Background: Behaviors that are performed repeatedly, excessively or minimally and…
  • MDS Virtual Congress 2021

    Apathy Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial

    T. Stiep, A. Ramirez-Zamora, A. Tröster, R. Jain, L. Chen, M. Okun (Gainesville, USA)

    Objective: To determine frequency and predictors of improvement or worsening of apathy in participants receiving bilateral subthalamic deep brain stimulation (STN-DBS) for the treatment of…
  • MDS Virtual Congress 2021

    Dopamine dysregulation syndrome in Parkinson’s disease after COVID-19. Case report.

    A. Nikitina, D. Degterev (Moscow, Russian Federation)

    Objective: To describe a case of a man with Parkinson’s disease (PD), who was developed dopamine dysregulation syndrome (DDS) after COVID-19. Background: Parkinson’s disease is…
  • MDS Virtual Congress 2020

    Sex-specific neuroprotection by inhibition of the Y-chromosome gene, SRY, in experimental Parkinson’s disease

    J. Lee, P. Pinares-Garcia, H. Loke, S. Ham, E. Vilain, V. Harley (Clayton, Australia)

    Objective: Given the presence and function of SRY in male DA (dopamine) neurons, we hypothesised that dysregulation of SRY may contribute to male susceptibility to…
  • MDS Virtual Congress 2020

    Maladaptive use of LD/CD tablets as painkillers causing Dopamine Dysregulation Syndrome in 4 patients of Advanced Parkinson’s Disease

    M. Gautam, K. Shukla, N. Sawal (Chandigarh, India)

    Objective: To study four cases of maladaptive use of levodopa/carbidopa (LD/CD) as painkillers causing Dopamine dysregulation syndrome (DDS) in Parkinson’s disease (PD) patient in a…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley